Click here to close now.

Welcome!

News Feed Item

Stock Price Movements, Completion of Acquisitions, and Clinical Trial Initiations - Research Report on Endocyte, PharMerica, Synta, AtriCure, and Cytokinetics

NEW YORK, January 15, 2014 /PRNewswire/ --


Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Endocyte, Inc. (NASDAQ: ECYT), PharMerica Corporation (NYSE: PMC), Synta Pharmaceuticals Corp. (NASDAQ: SNTA), AtriCure, Inc. (NASDAQ: ATRC), and Cytokinetics, Incorporated (NASDAQ: CYTK). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Endocyte, Inc. Research Report

On January 10, 2014, Endocyte, Inc.'s (Endocyte) stock ended the day at $14.02, compared to the previous closing price at $10.90, representing a significant 28.62% growth. The Company's stock grew 28.04% over the past three trading days, compared to the Dow Jones Industrial Average Index which declined 0.57% during the same period. The Full Research Report on Endocyte, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=DDD

http://www.analystscorner.com/r/full_research_report/fdf5_ECYT

--

PharMerica Corporation Research Report

On January 10, 2014, PharMerica Corp. (PharMerica) announced that it has completed acquisition of BGS Pharmacy Partners Inc. (BGS) in an all-cash transaction. Greg Weishar, PharMerica's CEO, stated, "The transaction increases our presence in two important markets where we have existing operations, Las Vegas and Salt Lake City, and expands our geographic footprint in the Reno area. BGS has a talented team and has built a strong business based on patient care, clinical expertise, and customer service. We look forward to working with BGS' outstanding client base to serve the needs of their residents." The Company informed that it expects the acquisition to be accretive to its earnings in 2014. The Full Research Report on PharMerica Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/b04b_PMC

--

Synta Pharmaceuticals Corp. Research Report  

On January 9, 2014, Synta Pharmaceuticals Corp. (Synta) announced the initiation of three multicenter, randomized Phase II/III Trials, evaluating ganetespib in combination with chemotherapy in first-line treatment of patients with AML and high risk MDS. According to the Company, preclinical results from Synta and its collaborators, Alan K. Burnett of Cardiff University and Sanjay Bansal of the UT Health Science Center at San Antonio, have shown that ganetespib inhibits a number of cancer-promoting factors believed to contribute to the proliferation of leukemic cells and renders them more vulnerable to treatment with chemotherapy. "The selection of ganetespib for three major potentially registration-enabling trials in AML is an exciting validation of the clinical potential of ganetespib, and reinforces our strategy of continuing to expand the depth and breadth of the ganetespib program through collaborations with strong groups of investigators," said Safi R. Bahcall, Ph.D., President and CEO of Synta. "Promising preclinical and early clinical results have been observed with ganetespib and other Hsp90 inhibitors in AML. We are pleased by the decision of the Leukemia & Lymphoma Research Fund, the Cancer Research UK, and the trial investigators to invest in moving ganetespib forward into three large, randomized trials, which we hope will ultimately lead to new options for patients with this devastating disease." The Full Research Report on Synta Pharmaceuticals Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/8ecc_SNTA

--

AtriCure, Inc. Research Report

On January 2, 2014, AtriCure, Inc. (AtriCure) announced the completion of the previously announced acquisition of Endoscopic Technologies, Inc. (Estech). Mike Carrel, President and CEO of AtriCure, said, "We are pleased to complete the acquisition of Estech, and we welcome the team to AtriCure. This transaction provides substantial benefits to AtriCure and strengthens our leadership position in the atrial fibrillation market; we are excited about the opportunities that our combined businesses will bring to our customers." AtriCure informed that it expects the transaction to increase sales and marketing expense as well as research and development expenditures in order to accelerate clinical development and commercial sales of the combined product portfolio. AtriCure further expects the transaction to be dilutive to earnings in 2014 and accretive in 2015 and beyond. The Full Research Report on AtriCure, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:  

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/f01d_ATRC

--

Cytokinetics, Incorporated Research Report    

On January 10, 2014, Cytokinetics, Inc.'s (Cytokinetics) stock ended the day at $9.58, compared to the previous closing price at $8.35, representing a 14.73% growth. The Company's stock grew 22.51% over the past three trading days, compared to the Dow Jones Industrial Average Index which declined 0.57% over the same trading period. The Full Research Report on Cytokinetics, Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/5338_CYTK

----

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

  1. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
  2. For any urgent concerns or inquiries, please contact us at [email protected].
  3. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


SOURCE Analysts' Corner

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
DevOps Summit, taking place Nov 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 17th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long development...
Live Webinar with 451 Research Analyst Peter Christy. Join us on Wednesday July 22, 2015, at 10 am PT / 1 pm ET In a world where users are on the Internet and the applications are in the cloud, how do you maintain your historic SLA with your users? Peter Christy, Research Director, Networks at 451 Research, will discuss this new network paradigm, one in which there is no LAN and no WAN, and discuss what users and network administrators gain and give up when migrating to the agile world of clo...
DevOps is about increasing efficiency, but nothing is more inefficient than building the same application twice. However, this is a routine occurrence with enterprise applications that need both a rich desktop web interface and strong mobile support. With recent technological advances from Isomorphic Software and others, it is now feasible to create a rich desktop and tuned mobile experience with a single codebase, without compromising performance or usability.
Containers are revolutionizing the way we deploy and maintain our infrastructures, but monitoring and troubleshooting in a containerized environment can still be painful and impractical. Understanding even basic resource usage is difficult – let alone tracking network connections or malicious activity. In his session at DevOps Summit, Gianluca Borello, Sr. Software Engineer at Sysdig, will cover the current state of the art for container monitoring and visibility, including pros / cons and liv...
SYS-CON Media announced today that CloudBees, the Jenkins Enterprise company, has launched ad campaigns on SYS-CON's DevOps Journal. CloudBees' campaigns focus on the business value of Continuous Delivery and how it has been recognized as a game changer for IT and is now a top priority for organizations, and the best ways to optimize Jenkins to ensure your continuous integration environment is optimally configured.
The 4th International Internet of @ThingsExpo, co-located with the 17th International Cloud Expo - to be held November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA - announces that its Call for Papers is open. The Internet of Things (IoT) is the biggest idea since the creation of the Worldwide Web more than
SYS-CON Events announced today that ProfitBricks, the provider of painless cloud infrastructure, will exhibit at SYS-CON's 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. ProfitBricks is the IaaS provider that offers a painless cloud experience for all IT users, with no learning curve. ProfitBricks boasts flexible cloud servers and networking, an integrated Data Center Designer tool for visual control over the...
"In the IoT space we are helping customers, mostly enterprises and industry verticals where time-to-value is critical, and we help them with the ability to do faster insights and actions using our platform so they can transform their business operations," explained Venkat Eswara, VP of Marketing at Vitria, in this SYS-CON.tv interview at @ThingsExpo, held June 9-11, 2015, at the Javits Center in New York City.
The most often asked question post-DevOps introduction is: “How do I get started?” There’s plenty of information on why DevOps is valid and important, but many managers still struggle with simple basics for how to initiate a DevOps program in their business. They struggle with issues related to current organizational inertia, the lack of experience on Continuous Integration/Delivery, understanding where DevOps will affect revenue and budget, etc. In their session at DevOps Summit, JP Morgenthal...
"We provide a web application framework for building really sophisticated web applications that run on a browser without any installation need so we get used for biotech, defense, and banking applications," noted Charles Kendrick, CTO and Chief Architect at Isomorphic Software, in this SYS-CON.tv interview at @DevOpsSummit (http://DevOpsSummit.SYS-CON.com), held June 9-11, 2015, at the Javits Center in New York
In his session at 16th Cloud Expo, Simone Brunozzi, VP and Chief Technologist of Cloud Services at VMware, reviewed the changes that the cloud computing industry has gone through over the last five years and shared insights into what the next five will bring. He also chronicled the challenges enterprise companies are facing as they move to the public cloud. He delved into the "Hybrid Cloud" space and explained why every CIO should consider ‘hybrid cloud' as part of their future strategy to achie...
"Plutora provides release and testing environment capabilities to the enterprise," explained Dalibor Siroky, Director and Co-founder of Plutora, in this SYS-CON.tv interview at @DevOpsSummit, held June 9-11, 2015, at the Javits Center in New York City.
DevOps tends to focus on the relationship between Dev and Ops, putting an emphasis on the ops and application infrastructure. But that’s changing with microservices architectures. In her session at DevOps Summit, Lori MacVittie, Evangelist for F5 Networks, will focus on how microservices are changing the underlying architectures needed to scale, secure and deliver applications based on highly distributed (micro) services and why that means an expansion into “the network” for DevOps.
"The idea of polyglot persistence is you have to apply the right database for the job - you always have to have many different databases in play. We offer that whole system as a service," explained Raj Singh, Developer Advocate for IBM Cloud Data Services, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
SYS-CON Events announced today that WHOA.com, an ISO 27001 Certified secure cloud computing company, participated as “Bronze Sponsor” of SYS-CON's 16th International Cloud Expo® New York, which took place June 9-11, 2015, at the Javits Center in New York City, NY. WHOA.com is a leader in next-generation, ISO 27001 Certified secure cloud solutions. WHOA.com offers a comprehensive portfolio of best-in-class cloud services for business including Infrastructure as a Service (IaaS), Secure Cloud Desk...